View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCofinimmo 将来の成長Future 基準チェック /06Cofinimmoの収益は年間0.6%で減少すると予測されていますが、年間利益は年間2.8%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に7% 5.9%なると予測されています。主要情報2.8%収益成長率5.93%EPS成長率Health Care REITs 収益成長23.3%収益成長率-0.6%将来の株主資本利益率7.02%アナリストカバレッジGood最終更新日15 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 10Cofinimmo SA(ENXTBR:COFB) dropped from Brussels BEL 20 IndexCofinimmo SA removedお知らせ • Oct 03+ 4 more updatesCofinimmo SA to Report Nine Months, 2026 Results on Oct 23, 2026Cofinimmo SA announced that they will report nine months, 2026 results on Oct 23, 2026お知らせ • May 15Cofinimmo SA announces Annual dividend, payable on May 22, 2025Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025.お知らせ • Jul 26+ 4 more updatesCofinimmo SA to Report Q3, 2025 Results on Oct 31, 2025Cofinimmo SA announced that they will report Q3, 2025 results Pre-Market on Oct 31, 2025Reported Earnings • Apr 27First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023)First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 08Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 25Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €71.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Health Care REITs industry globally. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €88.36 per share.お知らせ • Oct 28+ 5 more updatesCofinimmo SA to Report First Half, 2024 Results on Jul 26, 2024Cofinimmo SA announced that they will report first half, 2024 results on Jul 26, 2024お知らせ • Oct 07Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,785,805 Price\Range: €60 Transaction Features: Rule 144Aお知らせ • Sep 27An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million.An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023.お知らせ • Jul 14Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million.Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023.Buying Opportunity • Jun 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €94.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 0.1% per annum. Earnings is also forecast to grow by 4.5% per annum over the same time period.Buying Opportunity • May 19Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €95.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period.Upcoming Dividend • May 08Upcoming dividend of €4.34 per share at 7.2% yieldEligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of British dividend payers (5.7%). Higher than average of industry peers (6.5%).Reported Earnings • May 03First quarter 2023 earnings released: EPS: €0.53 (vs €5.28 in 1Q 2022)First quarter 2023 results: EPS: €0.53 (down from €5.28 in 1Q 2022). Revenue: €85.0m (up 6.3% from 1Q 2022). Net income: €17.5m (down 90% from 1Q 2022). Profit margin: 21% (down from 209% in 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 22Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 28% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the REITs industry in the United Kingdom.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €83.90, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the REITs industry in the United Kingdom. Total loss to shareholders of 28% over the past three years.Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.0% compared to a 7.1% growth forecast for the industry in the United Kingdom.お知らせ • Jul 30+ 4 more updatesCofinimmo SA to Report Fiscal Year 2022 Final Results on Apr 07, 2023Cofinimmo SA announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 07, 2023Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 09Upcoming dividend of €4.20 per shareEligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of British dividend payers (4.8%). Higher than average of industry peers (3.2%).Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.Board Change • Apr 28Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.Board Change • Feb 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020)Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Board Change • Oct 22Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 03Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 10Upcoming dividend of €4.06 per shareEligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of British dividend payers (4.0%). Higher than average of industry peers (3.0%).Reported Earnings • May 01First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Apr 15Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Feb 28Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 4.8% decline forecast for the REITs industry in the United Kingdom.Is New 90 Day High Low • Feb 09New 90-day high: €129The company is up 1.0% from its price of €129 on 10 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share.Reported Earnings • Jan 17Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.業績と収益の成長予測BATS-CHIXE:COFBB - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202838221389N/A312/31/2027369225105N/A712/31/2026356223123N/A23/31/2026383203N/AN/AN/A12/31/2025382213297297N/A9/30/2025390192N/AN/AN/A6/30/2025391134288288N/A3/31/2025392111N/AN/AN/A12/31/202439264279279N/A9/30/2024392-52N/AN/AN/A6/30/2024392-41254255N/A3/31/2024391-55N/AN/AN/A12/31/2023389-55227228N/A9/30/202337949N/AN/AN/A6/30/2023379185223224N/A3/31/2023373333N/AN/AN/A12/31/2022368483209210N/A9/30/2022367565N/AN/AN/A6/30/2022357489205206N/A3/31/2022351382N/AN/AN/A12/31/2021343260199200N/A9/30/2021328189N/AN/AN/A6/30/2021312155185186N/A3/31/2021276122N/AN/AN/A12/31/2020293119178180N/A9/30/2020296170N/AN/AN/A6/30/2020266193166167N/A3/31/2020292222N/AN/AN/A12/31/2019285205N/A169N/A9/30/2019241134N/AN/AN/A6/30/2019270119N/A182N/A3/31/2019259105N/AN/AN/A12/31/2018263146N/A161N/A9/30/2018260186N/AN/AN/A6/30/2018258170N/A140N/A3/31/2018264166N/AN/AN/A12/31/2017263137N/A157N/A9/30/2017267121N/AN/AN/A6/30/2017267128N/A168N/A3/31/2017275134N/AN/AN/A12/31/201625797N/A144N/A9/30/2016253100N/AN/AN/A6/30/201625582N/A148N/A3/31/2016249110N/AN/AN/A12/31/2015255104N/A170N/A9/30/201526076N/AN/AN/A6/30/201526266N/A158N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: COFBBの予測収益成長率 (年間2.8% ) は 貯蓄率 ( 3.4% ) を下回っています。収益対市場: COFBBの収益 ( 2.8% ) UK市場 ( 11.4% ) よりも低い成長が予測されています。高成長収益: COFBBの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: COFBBの収益は今後 3 年間で減少すると予想されています (年間-0.6% )。高い収益成長: COFBBの収益は今後 3 年間で減少すると予測されています (年間-0.6% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COFBBの 自己資本利益率 は、3年後には低くなると予測されています ( 7 %)。成長企業の発掘7D1Y7D1Y7D1YReal-estate 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/16 09:05終値2026/02/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cofinimmo SA 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Celine HuynhBarclaysKai KloseBerenbergRobert JonesBNP Paribas15 その他のアナリストを表示
お知らせ • Oct 03+ 4 more updatesCofinimmo SA to Report Nine Months, 2026 Results on Oct 23, 2026Cofinimmo SA announced that they will report nine months, 2026 results on Oct 23, 2026
お知らせ • May 15Cofinimmo SA announces Annual dividend, payable on May 22, 2025Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025.
お知らせ • Jul 26+ 4 more updatesCofinimmo SA to Report Q3, 2025 Results on Oct 31, 2025Cofinimmo SA announced that they will report Q3, 2025 results Pre-Market on Oct 31, 2025
Reported Earnings • Apr 27First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023)First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 08Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 25Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €71.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Health Care REITs industry globally. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €88.36 per share.
お知らせ • Oct 28+ 5 more updatesCofinimmo SA to Report First Half, 2024 Results on Jul 26, 2024Cofinimmo SA announced that they will report first half, 2024 results on Jul 26, 2024
お知らせ • Oct 07Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,785,805 Price\Range: €60 Transaction Features: Rule 144A
お知らせ • Sep 27An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million.An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023.
お知らせ • Jul 14Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million.Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023.
Buying Opportunity • Jun 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €94.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 0.1% per annum. Earnings is also forecast to grow by 4.5% per annum over the same time period.
Buying Opportunity • May 19Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €95.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period.
Upcoming Dividend • May 08Upcoming dividend of €4.34 per share at 7.2% yieldEligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of British dividend payers (5.7%). Higher than average of industry peers (6.5%).
Reported Earnings • May 03First quarter 2023 earnings released: EPS: €0.53 (vs €5.28 in 1Q 2022)First quarter 2023 results: EPS: €0.53 (down from €5.28 in 1Q 2022). Revenue: €85.0m (up 6.3% from 1Q 2022). Net income: €17.5m (down 90% from 1Q 2022). Profit margin: 21% (down from 209% in 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 22Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 28% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the REITs industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €83.90, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the REITs industry in the United Kingdom. Total loss to shareholders of 28% over the past three years.
Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.0% compared to a 7.1% growth forecast for the industry in the United Kingdom.
お知らせ • Jul 30+ 4 more updatesCofinimmo SA to Report Fiscal Year 2022 Final Results on Apr 07, 2023Cofinimmo SA announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 07, 2023
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 09Upcoming dividend of €4.20 per shareEligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of British dividend payers (4.8%). Higher than average of industry peers (3.2%).
Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.
Board Change • Apr 28Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.
Board Change • Feb 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020)Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Board Change • Oct 22Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 03Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 10Upcoming dividend of €4.06 per shareEligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of British dividend payers (4.0%). Higher than average of industry peers (3.0%).
Reported Earnings • May 01First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 15Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 28Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 4.8% decline forecast for the REITs industry in the United Kingdom.
Is New 90 Day High Low • Feb 09New 90-day high: €129The company is up 1.0% from its price of €129 on 10 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share.
Reported Earnings • Jan 17Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.